The changing landscape of therapeutic strategies for recurrent ovarian cancer

Future Oncol. 2012 Sep;8(9):1135-47. doi: 10.2217/fon.12.112.


Advanced epithelial ovarian cancer, cancer of the fallopian tube and primary peritoneal cancer have a poor prognosis and a high rate of disease recurrence following primary therapy. Recurrent ovarian cancer is currently classified according to sensitivity to platinum-based chemotherapy. Data on targeted therapy provide evidence of improvement with systemic treatment in addition to chemotherapy. Other strategies, although not proven in randomized trials, offer interesting options for future research and therapeutic development. In this review, the covered treatment modalities include surgery, chemotherapy and targeted therapy, immunological approaches and irradiation.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Cancer Vaccines / pharmacology
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Molecular Targeted Therapy
  • Neoplasm Recurrence, Local / therapy*
  • Oncolytic Virotherapy
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy*


  • Antineoplastic Agents
  • Cancer Vaccines